Cardiac valve calcification and use of anticoagulants: Preliminary observation of a potentially modifiable risk factor

Direct oral anticoagulant (DOAC) has been recently introduced in the clinical practice. Rather than interfering with vitamin K-dependent posttranscriptional modification of various proteins, DOACs selectively inhibit factors involved in the coagulation cascade. In particular, in contrast with Warfarin, Rivaroxabn does not interfere with activation of matrix Gla Protein (MGP), a potent vascular calcification Inhibitor. We herein sought to investigate the impact of Rivaroxaban and Warfarin on cardiac valve calcifications in a cohort of moderate-to advanced CKD patients.

Source: International Journal of Cardiology - November 29, 2018 Category: Cardiology Authors: Luca Di Lullo, Giovanni Tripepi, Claudio Ronco, Graziella D'Arrigo, Vincenzo Barbera, Domenico Russo, Biagio Raffaele Di Iorio, Massimo Uguccioni, Ernesto Paoletti, Maura Ravera, Maria Fusaro, Antonio Bellasi Source Type: research